Tuberculosis Therapy
Rifamycin resistance risk similar for rifampin and rifabutin DOT regimens
Published in AIDS Weekly, April 5th, 2004
In a recent study, scientists in Tennessee "sought to determine the risk of acquired rifamycin-resistant (ARR) tuberculosis associated with rifampin-versus rifabutin-based directly observed therapy and to assess the risk factors for relapse of tuberculosis."
"This observational cohort study included patients with culture-confirmed rifamycin-susceptible tuberculosis reported to the Baltimore City Health Department (Baltimore, MD) during the period of January 1993 through December 2001," explained R.E. Nettles and coauthors at Vanderbilt University. "Of the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2004-04-05)
More Articles from AIDS Weekly
- Drug Development
Cell-penetrating, Rev-binding peptides can protect against HIV - Drug Development
Fungal derivatives show promise as HIV integrase inhibitors - Drug Development
Novel benzophenones show promise as anti-HIV NNRTIs - HIV/AIDS Therapy
Hepatotoxic effects comparable for all ARVs - HIV/AIDS Therapy
Routine resistance testing can improve ART outcome in experienced patients - HIV/AIDS Women's Health
Vitamin A supplements may increase risk of vertical HIV transmission - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
